Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04656418
Recruitment Status : Completed
First Posted : December 7, 2020
Last Update Posted : January 13, 2023
Information provided by (Responsible Party):
CSL Behring

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 7, 2022
Actual Study Completion Date : June 7, 2022
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 June 7, 2023